Abemaciclib, sold under the brand name Ramiven among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.<\/p>\n
Since September 2017, abemaciclib has been approved in the US for “adults who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones”.<\/p>\n
In studies that compared fulvestrant plus abemaciclib to fulvestrant plus placebo in breast cancer patients, progression-free survival under abemaciclib therapy was 16.4 months on average, as compared to 9.3 months under the placebo arm.<\/p>\n
For inquiries regarding availability, import process, or cost of Ramiven (abemaciclib):<\/strong> NEWS\/UPDATES<\/p>\n India Pharma Network acts solely as a facilitator for Ramiven (abemaciclib) access. IPN does not manufacture, sell, or promote medicines and does not provide medical advice. All imports are:<\/p>\n The prescribing physician remains solely responsible for dosage, therapy, and clinical decisions.<\/p>\n","protected":false},"excerpt":{"rendered":" It is an anti-cancer drug indicated for specific types of breast cancer, primarily HR-positive, HER2-negative breast cancer, both locally advanced\/metastatic and as adjuvant therapy for high-risk early-stage cases, used with other hormonal treatments. It works by blocking CDK4\/6 proteins to slow cancer cell growth and prevent recurrence.<\/p>\n
\nIndia Pharma Network (IPN)<\/strong>\u00a0: Headquartered in\u00a0New Delhi<\/strong>, with branch offices in\u00a0Delhi, Gurugram, Mumbai, Bangalore, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur\u00a0<\/strong>and\u00a0Lucknow<\/strong>, IPN supports medicine imports across India on a\u00a0Named Patient Basis<\/strong>\u00a0and for\u00a0personal use only<\/strong>.\u00a0Mobile\/WhatsApp:<\/strong>\u00a0Mr. Tarun: +91 9891 296 838 | \u00a0Mr. Neeraj: +91 9811 747 774.\u00a0Email:<\/strong>\u00a0info@indianpharmanetwork.co.in<\/a><\/p>\n\n
Compliance & Disclaimer<\/h5>\n
\n
Ramiven (abemaciclib) \u2013 Breast Cancer Therapy in India<\/h2>\n
\n\n
\n Brand Name:<\/strong><\/td>\n Ramiven<\/td>\n<\/tr>\n \n Generic Name:<\/strong><\/td>\n Abemaciclib Tablets<\/td>\n<\/tr>\n \n Strength:<\/strong><\/td>\n \u2022 Tablets: 150 mg<\/td>\n<\/tr>\n \n Manufacturer:<\/strong><\/td>\n Lilly<\/td>\n<\/tr>\n \n Approved By:<\/strong><\/td>\n EMA, USFDA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n